title: Functional polymorphisms in the human beta4 subunit of nicotinic acetylcholine receptors.
abstract: Human nicotinic acetylcholine receptor (nAChR) polymorphisms occur in different ethnic populations and may result in differences in nAChR ion channel properties. We have identified four nAChR beta 4 subunit (beta4) nucleotide variants: 392C-->T, 526C-->T, 538A-->G, and 1519A-->G. Their corresponding amino acid substitutions are: Thr to Ile at codon 91 (T91I), Arg to Trp at codon 136 (R136W), Ser to Gly at codon 140 (S140G), and Met to Val at codon 467 (M467V), respectively. The nAChR ion channel properties of these variants were studied and compared with the more-common (wild-type) allele as wild-types. The nAChRs (alpha4beta4 channels) were expressed heterologously in Xenopus oocytes and studied using the two-electrode voltage clamp technique to reveal functional differences between the wild-type and the variants. The receptors containing the R136W and M467V mutations (or variants) had a higher sensitivity to acetylcholine and lower EC50 than the wild-type. The T91I mutation had lower sensitivity to acetylcholine and the EC50 was larger than in wild-type nAChRs. The S140G mutation had a dose-response relationship that was similar to the wild-type. The T91I, R136W, and M467V mutations (or variants) also showed a slightly greater degree of steady-state desensitization than the wild-type in response to a 30-min exposure to one tenth of their EC50. The present results demonstrate that human beta4 nAChR DNA polymorphisms result in functional changes, and suggest that certain individuals with those variants may be more or less sensitive to cholinergic drugs or to dysfunctions associated with nicotinic cholinergic systems.
authors.affiliation: Department of Neuroscience, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Yong
authors.initials: Y
authors.lastname: Liang
authors.forename: Ramiro
authors.initials: R
authors.lastname: Salas
authors.forename: Lisa
authors.initials: L
authors.lastname: Marubio
authors.forename: Dani
authors.initials: D
authors.lastname: Bercovich
authors.forename: Mariella
authors.initials: M
authors.lastname: De Biasi
authors.forename: Arthur L
authors.initials: AL
authors.lastname: Beaudet
authors.forename: John A
authors.initials: JA
authors.lastname: Dani
mesh_terms: D019943:Amino Acid Substitution; D003062:Codon / Q000235:genetics; D017931:DNA Primers; D014644:Genetic Variation; D006801:Humans; D008564:Membrane Potentials / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000502:physiology; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D021122:Protein Subunits / Q000235:genetics; D011978:Receptors, Nicotinic / Q000235:genetics* / Q000502:physiology; D011994:Recombinant Proteins / Q000378:metabolism
chemical_list: C447159:CHRNB4 protein, human; D003062:Codon; D017931:DNA Primers; D009419:Nerve Tissue Proteins; D021122:Protein Subunits; D011978:Receptors, Nicotinic; D011994:Recombinant Proteins
references.citation: Brain Res Brain Res Rev. 1998 May;26(2-3):198-216
references.pmid: 9651527
references.citation: J Comp Neurol. 2000 Sep 11;425(1):58-69
references.pmid: 10940942
references.citation: J Neurosci. 1999 Nov 1;19(21):9298-305
references.pmid: 10531434
references.citation: Neuron. 1996 May;16(5):905-8
references.pmid: 8630247
references.citation: Nature. 2004 Aug 19;430(7002):896-900
references.pmid: 15318223
references.citation: Nature. 1999 Apr 29;398(6730):805-10
references.pmid: 10235262
references.citation: Neuroscience. 1998 Dec;87(3):659-73
references.pmid: 9758232
references.citation: Addict Behav. 2004 Feb;29(2):261-72
references.pmid: 14732415
references.citation: Trends Neurosci. 2002 Apr;25(4):171-2
references.pmid: 11998680
references.citation: Pharmacol Biochem Behav. 2001 Dec;70(4):439-46
references.pmid: 11796143
references.citation: J Comp Neurol. 1989 Jun 8;284(2):314-35
references.pmid: 2754038
references.citation: Biophys J. 1994 Mar;66(3 Pt 1):646-53
references.pmid: 7516721
references.citation: Mol Pharmacol. 2002 Mar;61(3):695-705
references.pmid: 11854451
references.citation: J Neurosci. 2001 Mar 1;21(5):1452-63
references.pmid: 11222635
references.citation: J Neurobiol. 2002 Dec;53(4):431-46
references.pmid: 12436411
references.citation: Science. 1984 Sep 21;225(4668):1335-45
references.pmid: 6382611
references.citation: Lancet. 1992 May 23;339(8804):1268-78
references.pmid: 1349675
references.citation: Eur J Neurosci. 1995 Apr 1;7(4):647-55
references.pmid: 7620615
references.citation: Mol Pharmacol. 2003 Mar;63(3):574-80
references.pmid: 12606764
references.citation: Neuropharmacology. 2004 Sep;47(3):401-7
references.pmid: 15275829
references.citation: Nat Genet. 1995 Oct;11(2):201-3
references.pmid: 7550350
references.citation: Epilepsia. 2002;43 Suppl 5:112-22
references.pmid: 12121305
references.citation: Tob Control. 2000;9 Suppl 2:II4-8
references.pmid: 10841585
references.citation: Biophys J. 1996 Oct;71(4):1659-71
references.pmid: 8889144
references.citation: J Neurosci. 2000 Jan 1;20(1):66-75
references.pmid: 10627582
references.citation: Nature. 2003 Jun 26;423(6943):949-55
references.pmid: 12827192
references.citation: Nature. 2001 Feb 15;409(6822):928-33
references.pmid: 11237013
references.citation: Eur J Neurosci. 1994 Mar 1;6(3):478-85
references.pmid: 8019684
references.citation: J Pharmacol Exp Ther. 1997 Jan;280(1):346-56
references.pmid: 8996215
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2786-91
references.pmid: 11226318
references.citation: Nature. 1997 Nov 27;390(6658):401-4
references.pmid: 9389479
references.citation: Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7280-4
references.pmid: 7688475
references.citation: Br J Pharmacol. 1998 Oct;125(4):751-60
references.pmid: 9831911
references.citation: Biochemistry. 2000 Apr 25;39(16):4666-73
references.pmid: 10769122
references.citation: Nat Rev Neurosci. 2002 Feb;3(2):102-14
references.pmid: 11836518
references.citation: Eur J Neurosci. 1994 Oct 1;6(10):1596-604
references.pmid: 7850023
references.citation: J Biol Chem. 1996 Jul 26;271(30):17656-65
references.pmid: 8663494
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:431-58
references.pmid: 10836143
references.citation: Brain Res Mol Brain Res. 1992 Dec;16(3-4):339-44
references.pmid: 1337943
references.citation: Biophys J. 1984 Aug;46(2):277-83
references.pmid: 6478036
references.citation: J Physiol Paris. 1998 Apr;92(2):63-74
references.pmid: 9782446
references.citation: J Neurosci. 2003 Jul 16;23(15):6255-63
references.pmid: 12867510
references.citation: Nature. 1991 Oct 31;353(6347):846-9
references.pmid: 1719423
references.citation: J Neurosci. 1993 Jun;13(6):2680-8
references.pmid: 8501532
references.citation: J Hum Genet. 2001;46(7):362-6
references.pmid: 11450844
references.citation: Genet Test. 2003 Fall;7(3):189-94
references.pmid: 14641994
references.citation: J Gen Physiol. 2002 Oct;120(4):483-96
references.pmid: 12356851
references.citation: Am J Hum Genet. 2001 Jan;68(1):225-31
references.pmid: 11104662
references.citation: Neuron. 2001 Jul 19;31(1):131-41
references.pmid: 11498056
references.citation: Learn Mem. 2004 Jan-Feb;11(1):60-9
references.pmid: 14747518
references.citation: Neuropharmacology. 1999 Jun;38(6):769-83
references.pmid: 10465681
references.citation: Nature. 2001 May 17;411(6835):269-76
references.pmid: 11357122
references.citation: Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12689-94
references.pmid: 9770547